Pneumonia, Pneumococcal Therapeutic Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Pneumonia, Pneumococcal Therapeutic Market is segmented By Route of Administration (Oral, Intravenous, Subcutaneous, Parenteral, Topical), By Molecule Type (Recombinant Fusion Proteins, Small Molecule, Monoclonal Antibody, Peptide Polymer, Gene Therapy), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Pneumonia, Pneumococcal Therapeutic Market Size
Taille du Marché en USD Bn
TCAC8.4%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 8.4% |
| Concentration du Marché | Medium |
| Principaux Acteurs | Biotest AG, Vaxcyte, Inc., Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc. and Among Others. |
please let us know !
Pneumonia, Pneumococcal Therapeutic Market Analysis
The pneumonia, pneumococcal therapeutic market is estimated to be valued at USD 2.72 Billion in 2024 and is expected to reach USD 4.77 Billion by 2031, growing at a compound annual growth rate (CAGR) of 8.4% from 2024 to 2031. The growing geriatric population and increased risk of pneumonia among the elderly is driving the demand. Furthermore, rising pollution levels and environmental factors leading to higher prevalence of respiratory illnesses are also boosting the market growth.